Advertisement

Internal Medicine Physicians’ Financial Relationships with Industry: An Updated National Estimate

  • Aaron S. Kesselheim
  • Steven Woloshin
  • Zhigang Lu
  • Frazer A. Tessema
  • Kathryn M. Ross
  • Lisa M. Schwartz
Concise Research Reports

INTRODUCTION

Financial relationships between physicians and prescription drug or medical device manufacturers remain controversial. Recent large national studies have shown such relationships are associated with prescription of brand-name drugs, especially those sold by the sponsoring manufacturer, over equally effective lower-cost generics.1, 2

Since 2013, industry payments and gifts are being publicly reported. Also, some large academic medical centers, physician employers, such as Kaiser Permanente, and states have banned or restricted detailing visits, physician payments, or gifts, and some manufacturers have changed their own practices for certain gifts.3 We conducted a national survey of internal medicine physicians to assess how their financial relationships with industry have changed in this context.

METHODS

We randomly sampled 500 clinically active internists and 1000 internal medicine specialists (500 endocrinologists, 500 cardiologists) from the American Board of Internal...

Notes

Acknowledgements

The authors would like to thank Doris Peter, Ph.D., Yale School of Medicine, for her help in implementing the study.

Funding

Work at PORTAL on this project was funded by the Laura and John Arnold Foundation. Dr. Kesselheim also receives support from the Harvard Program in Therapeutic Science and the Engelberg Foundation. Survey honoraria and administrative costs were provided by Consumer Union.

Compliance with Ethical Standards:

The Dartmouth College IRB approved the project.

Conflict of Interest

Drs. Schwartz and Woloshin were co-founders of Informulary, Inc., a company that provides data about the benefits, harms, and uncertainties of prescription drugs, which ceased operations in December 2016. Dr. Kesselheim reports serving as an expert witness for the plaintiffs in the Multidistrict Opiate Litigation on the subject of pharmaceutical marketing. All other authors declare that they do not have a conflict of interest.

References

  1. 1.
    DeJong C, Aguilar T, Tseng CW, Lin GA, Boscardin WJ, Dudley RA. Pharmaceutical industry-sponsored meals and physician prescribing patterns for medicare beneficiaries. JAMA Intern Med 2016;176(8):1114–1122.CrossRefGoogle Scholar
  2. 2.
    Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ 2016;354:i4189.CrossRefGoogle Scholar
  3. 3.
    Larkin I, Ang D, Avorn J, Kesselheim AS. Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children. Health Affairs 2014;33(6):1014–1023.CrossRefGoogle Scholar
  4. 4.
    Campbell EG, Rao SR, DesRoches CM, Iezzoni LI, Vogeli C, Bolcic-Jankovic D, Miralles PD. Physician professionalism and changes in physician-industry relationships from 2004 to 2009. Arch Intern Med 2010;170(20):1820–1826.CrossRefGoogle Scholar
  5. 5.
    Fugh-Berman A and Ahari S. Following the script: how drug reps make friends and influence doctors. PLoS Medicine 2007;4: e150.CrossRefGoogle Scholar
  6. 6.
    Pinckney RG, Helminski AS, Kennedy AG, Maclean CD, Hurowitz L, Cote E. The effect of medication samples on self-reported prescribing practices: a statewide, cross-sectional survey. J Gen Int Med 2011;26:40–44.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2018

Authors and Affiliations

  • Aaron S. Kesselheim
    • 1
  • Steven Woloshin
    • 2
  • Zhigang Lu
    • 1
  • Frazer A. Tessema
    • 1
  • Kathryn M. Ross
    • 3
  • Lisa M. Schwartz
    • 2
  1. 1.Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of MedicineBrigham and Women’s Hospital/Harvard Medical SchoolBostonUSA
  2. 2.Center for Medicine and the MediaDartmouth Institute for Health Policy and Clinical PracticeLebanonUSA
  3. 3.American Board of Internal Medicine in PhiladelphiaPhiladelphiaUSA

Personalised recommendations